Page 1 | Search Results | Blood | American Society of Hematology

1-9 of 9

Sort by

Sort Order Select

Journal Articles

Rituximab and Chlorambucil as Front-Line Treatment in Untreated Follicular Lymphoma: a Combination with a Durable Response and Low Toxicity Profile.

Simona Bassi, MD, Luca Nassi, MD, Giancarlo Pruneri, MD, Simona Sammassimo, MD, Paola Bertazzoni, MD, Federica Gigli, MD, Anna Vanazzi, MD, Emilia Cocorocchio, MD, Patrizia Mancuso, Cristina Rabascio, Maria Teresa Lionetti, Daniele Laszlo, MD, Giovanni Martinelli, MD

Blood (2009) 114 (22): 3754.

https://doi.org/10.1182/blood.V114.22.3754.3754

Published: 2009

Journal Articles

90 y-Ibritumomab Tiuxetan or Purine Analogues Severely Affect Peripheral Blood Stem Cell Mobilization: An Analysis On 248 Patients.

Anna Vanazzi, MD, Alessandra Alietti, MD, Alberto Agazzi, MD, Mara Negri, Maria Teresa Lionetti, Aleksandra Babic, Davide Radice, Luca Nassi, MD, Simona Sammassimo, MD, Cristina Rabascio, Pierluigi Antoniotti, Lara Roveda, Bruno Lucchetti, Tiziana Suardi, Alessio Piredda, Liliana Calabrese, Giovanni Martinelli, MD, Daniele Laszlo, MD

Blood (2009) 114 (22): 3210.

https://doi.org/10.1182/blood.V114.22.3210.3210

Published: 2009

Journal Articles

Dose-Dense CHOP Plus Rituximab (R-CHOP14) Seems To Overcome, in Large B Cell Lymphoma, the Negative Prognostic Significance of B Cell Origin.

Luigi Rigacci, MD, Luca Nassi, MD, Simonetta di Lollo, MD, Benedetta Puccini, MD, Morena Doria, MD, Silvia Mappa, MD, Gloria Capaccioli, Renato Alterini, MD, Valentina Carrai, MD, Alberto Bosi, MD

Blood (2007) 110 (11): 4401.

https://doi.org/10.1182/blood.V110.11.4401.4401

Published: 2007

Journal Articles

Combined VBM Chemotherapy and Involved Field (IF) Radiotherapy in Early Stage Hodgkin’s Lymphoma (HL): A Single Centre Experience.

Emilia Cocorocchio, MD, Fedro A. Peccatori, MD, Federica Gigli, MD, Simona Bassi, MD, Luca Nassi, MD, Liliana Calabrese, DSc, Laura Travaini, MD, Gaia Piperno, MD, Lorenzo Preda, MD, Giancarlo Pruneri, MD, Sarah J. Liptrott, BN, Alessandra Alietti, MD, Giovanni Martinelli, MD

Blood (2007) 110 (11): 4463.

https://doi.org/10.1182/blood.V110.11.4463.4463

Published: 2007

Journal Articles

Liposomal Doxorubicin in the Treatment of Elderly, Cardiopatic, or Pretreated Patients with Aggressive Lymphomas: Comparison with an Historical Series.

Luigi Rigacci, MD, Silvia Mappa, MD, Luca Nassi, MD, Renato Alterini, MD, Valentina Carrai, MD, Franco Bernardi, MD, Alberto Bosi, MD

Blood (2006) 108 (11): 4685.

https://doi.org/10.1182/blood.V108.11.4685.4685

Published: 2006

Journal Articles

First Line Treatment with Rituximab and Chlorambucil in the Treatment of Ocular Adnexal Lymphomas.

Luigi Rigacci, MD, Marco Puccioni, MD, Luca Nassi, MD, Silvia Mappa, MD, Cinzia Mazzini, MD, Renato Alterini, MD, Valentina Carrai, MD, Ennio Polito, MD, Alberto Bosi, MD

Blood (2006) 108 (11): 4712.

https://doi.org/10.1182/blood.V108.11.4712.4712

Published: 2006

Journal Articles

Comparison between 2-Deoxy-2-[18f]Fluoro-D-Glucose Positron Emission (FDG-PET) and Computed Tomography (CT) for Staging of Patients with Hodgkin’s Lymphoma (HL).

Luigi Rigacci, MD, Francesco Merli, MD, Antonio Castagnoli, MD, Annibale Versari, MD, Luca Nassi, MD, Ida Capodanno, MD, Teodoro Chisesi, MD, Andrea Gallamini, MD, Alberto Biggi, MD, Umberto Vitolo, MD, Silvia Tavera, MD, Rosaria Sancetta, MD, Patrizia Pregno, MD, Francesca Salvi, MD, Ettore Pelosi, MD, Alessandro Levis, MD, Alberto Bosi, MD.

Blood (2005) 106 (11): 975.

https://doi.org/10.1182/blood.V106.11.975.975

Published: 2005

Journal Articles

Predictive Value of 18 F-Fluorodeoxyglucose Positron Emission Tomography (FDG PET) Performed after Two Cycles of Standard Chemotherapy (CT) on Treatment Outcome in Hodgkin Disease.

Andrea Gallamini, MD, Luigi Rigacci, MD, Francesco Merli, MD, Pasquale Errico, MD, Alessandro Levis, MD, Alberto Biggi, MD, Antonio Castagnoli, MD, Silvia Tavera, MD, Luca Nassi, MD

Blood (2004) 104 (11): 310.

https://doi.org/10.1182/blood.V104.11.310.310

Published: 2004

Journal Articles

Intensified Chop (CHOP14) Plus Rituximab in the Treatment of Elderly Patients with Aggressive and High Risk Non Hodgkin’s Lymphoma (NHL).

Luigi Rigacci, MD, Luca Nassi, MD, Renato Alterini, MD, Valentina Carrai, MD, Franco Bernardi, MD, Varesco Martini, MD, Paolo Bernardeschi, MD, Giovanni Longo, MD, Alberto Bosi, MD

Blood (2004) 104 (11): 4577.

https://doi.org/10.1182/blood.V104.11.4577.4577

Published: 2004

NARROW

Rituximab and Chlorambucil as Front-Line Treatment in Untreated Follicular Lymphoma: a Combination with a Durable Response and Low Toxicity Profile.

90 y-Ibritumomab Tiuxetan or Purine Analogues Severely Affect Peripheral Blood Stem Cell Mobilization: An Analysis On 248 Patients.

Dose-Dense CHOP Plus Rituximab (R-CHOP14) Seems To Overcome, in Large B Cell Lymphoma, the Negative Prognostic Significance of B Cell Origin.

Combined VBM Chemotherapy and Involved Field (IF) Radiotherapy in Early Stage Hodgkin’s Lymphoma (HL): A Single Centre Experience.

Liposomal Doxorubicin in the Treatment of Elderly, Cardiopatic, or Pretreated Patients with Aggressive Lymphomas: Comparison with an Historical Series.

First Line Treatment with Rituximab and Chlorambucil in the Treatment of Ocular Adnexal Lymphomas.

Comparison between 2-Deoxy-2-[18f]Fluoro-D-Glucose Positron Emission (FDG-PET) and Computed Tomography (CT) for Staging of Patients with Hodgkin’s Lymphoma (HL).

Predictive Value of 18 F-Fluorodeoxyglucose Positron Emission Tomography (FDG PET) Performed after Two Cycles of Standard Chemotherapy (CT) on Treatment Outcome in Hodgkin Disease.

Intensified Chop (CHOP14) Plus Rituximab in the Treatment of Elderly Patients with Aggressive and High Risk Non Hodgkin’s Lymphoma (NHL).

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only